{"nctId":"NCT00856986","briefTitle":"The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes","startDateStruct":{"date":"2009-03"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":987,"armGroups":[{"label":"Lira 1.8","type":"EXPERIMENTAL","interventionNames":["Drug: liraglutide","Drug: metformin"]},{"label":"Insulin detemir + Lira 1.8","type":"EXPERIMENTAL","interventionNames":["Drug: liraglutide","Drug: insulin detemir","Drug: metformin"]},{"label":"Non-Randomised Lira 1.8","type":"EXPERIMENTAL","interventionNames":["Drug: liraglutide","Drug: metformin"]},{"label":"Early Withdrawals Lira 1.8","type":"OTHER","interventionNames":["Drug: liraglutide","Drug: metformin"]},{"label":"Intensified group","type":"OTHER","interventionNames":["Drug: liraglutide","Drug: insulin detemir","Drug: metformin"]}],"interventions":[{"name":"liraglutide","otherNames":[]},{"name":"insulin detemir","otherNames":[]},{"name":"metformin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects diagnosed with type 2 diabetes, insulin na√Øve and treated with metformin as monotherapy for at least 3 months prior to screening, at a stable dose of at least 1500 mg/day or metformin (at least 1500 mg/day) and a sulfonylurea (less than or equal to half of the maximum approved dose), both at a stable dose for at least 3 months prior to screening. Previous short-term insulin treatment in connection with intercurrent illness is allowed at the discretion of the Investigator\n* HbA1c 7.0-10.0% (both inclusive) for subjects on metformin monotherapy\n* HbA1c 7.0-8.5% (both inclusive) for subjects on metformin in combination with a sulphonylurea\n\nExclusion Criteria:\n\n* Previous treatment with insulin (except for short-term treatment in connection with intercurrent illness at the discretion of the Investigator)\n* Treatment with glucose-lowering agent(s) other than stated in the inclusion criteria in a period of 3 months prior to screening\n* Recurrent major hypoglycaemia or hypoglycaemic unawareness as judged by the Investigator\n* Impaired kidney function\n* Impaired liver function\n* Uncontrolled treated/untreated hypertension\n* Cancer or any clinically significant disease or disorder as judged by the Investigator\n* Previous participation in the run-in phase of this trial. Re-screening is allowed once\n* History of chronic pancreatitis or idiopathic pancreatitis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"84 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.07"},{"groupId":"OG001","value":"-0.51","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 (for Intensified Subjects in Original Treatment Group)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.09"},{"groupId":"OG001","value":"-0.51","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 (Values Before Intensification as LOCF)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.09"},{"groupId":"OG001","value":"-0.5","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Fasting Plasma Glucose at Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.39","spread":"0.19"},{"groupId":"OG001","value":"-2.12","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Fasting Plasma Glucose at Week 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.21"},{"groupId":"OG001","value":"-1.91","spread":"0.21"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in 7-point Plasma Glucose Profile (Self-measured) at Week 26","description":"Calculated as an estimate of the change in mean prandial increment of plasma glucose after breakfast, lunch and dinner (from baseline/randomisation (week 0) to 26 weeks), respectively. Prandial increments of plasma glucose were calculated as the difference between glucose values measured before and after each of these three meals, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.97","spread":"0.26"},{"groupId":"OG001","value":"-2.09","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"0.22"},{"groupId":"OG001","value":"-1.43","spread":"0.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.48","spread":"0.24"},{"groupId":"OG001","value":"-1.18","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in 7-point Plasma Glucose Profile (Self-measured) at Week 52","description":"Calculated as an estimate of the change in mean prandial increment of plasma glucose after breakfast, lunch and dinner (from baseline (week 0) to 52 weeks), respectively. Prandial increments of plasma glucose were calculated as the difference between glucose values measured before and after each of these three meals, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.68","spread":"0.25"},{"groupId":"OG001","value":"-2.43","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.51","spread":"0.25"},{"groupId":"OG001","value":"-1.14","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.96","spread":"0.26"},{"groupId":"OG001","value":"-1.4","spread":"0.25"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Fasting Insulin at Week 26","description":null,"classes":[]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Fasting Insulin at Week 52","description":null,"classes":[]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Fasting Pro-insulin at Week 26.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.12","spread":"3.27"},{"groupId":"OG001","value":"-9.78","spread":"3.22"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Fasting Pro-insulin at Week 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.47","spread":"3.08"},{"groupId":"OG001","value":"-4","spread":"3.08"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Fasting C-peptide at Week 26.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.04"},{"groupId":"OG001","value":"-0.32","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Fasting C-peptide at Week 52.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.05"},{"groupId":"OG001","value":"-0.34","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Mean Changes From Randomisation in Cholesterol Lipids at Week 26.","description":"Cholesterol Lipids cover: Total Cholesterol, Low-density Lipoprotein Cholesterol (LDL-C), Very Low Density Lipoprotein Cholesterol (VLDL-C), High Density Lipoprotein Cholesterol (HDL-C)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.07"},{"groupId":"OG001","value":"0.05","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.06"},{"groupId":"OG001","value":"-0.03","spread":"0.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.03"},{"groupId":"OG001","value":"0.01","spread":"0.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.01"},{"groupId":"OG001","value":"0.05","spread":"0.01"}]}]}]},{"type":"SECONDARY","title":"Mean Changes From Randomisation in Cholesterol Lipids at Week 52.","description":"Cholesterol Lipids cover: Total Cholesterol, Low-density Lipoprotein Cholesterol (LDL-C), Very Low Density Lipoprotein Cholesterol (VLDL-C), High Density Lipoprotein Cholesterol (HDL-C)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.08"},{"groupId":"OG001","value":"-0.03","spread":"0.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.07"},{"groupId":"OG001","value":"-0.1","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.04"},{"groupId":"OG001","value":"-0.03","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.02"},{"groupId":"OG001","value":"0.07","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Lipids: Triglycerides at Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"0.11"},{"groupId":"OG001","value":"-0.33","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Lipids: Triglycerides at Week 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":"0.11"},{"groupId":"OG001","value":"-0.37","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Lipids: Free Fatty Acids (FFA) at Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.02"},{"groupId":"OG001","value":"-0.11","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Lipids: Free Fatty Acids (FFA) at Week 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.03"},{"groupId":"OG001","value":"-0.07","spread":"0.03"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Body Weight at Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.95","spread":"0.31"},{"groupId":"OG001","value":"-0.16","spread":"0.31"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Body Weight at Week 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.02","spread":"0.41"},{"groupId":"OG001","value":"-0.05","spread":"0.42"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Waist Circumference at Week 26.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.66","spread":"0.46"},{"groupId":"OG001","value":"-0.78","spread":"0.46"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Waist Circumference at Week 52.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"0.54"},{"groupId":"OG001","value":"-0.83","spread":"0.53"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Hip Circumference at Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.36","spread":"0.46"},{"groupId":"OG001","value":"-0.38","spread":"0.45"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Hip Circumference at Week 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.79","spread":"0.5"},{"groupId":"OG001","value":"-0.28","spread":"0.49"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Waist to Hip Ratio at Week 26","description":"Waist to Hip Ratio is calculated by dividing Waist circumference with Hip circumference","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.00356","spread":"0.004071"},{"groupId":"OG001","value":"-0.00332","spread":"0.004032"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Waist to Hip Ratio at Week 52","description":"Waist to Hip Ratio is calculated by dividing Waist circumference with Hip circumference","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.00146","spread":"0.004165"},{"groupId":"OG001","value":"-0.00438","spread":"0.004126"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Blood Pressure (Systolic and Diastolic) at Week 26.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.11","spread":"1.22"},{"groupId":"OG001","value":"0.41","spread":"1.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"0.77"},{"groupId":"OG001","value":"-0.4","spread":"0.78"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Randomisation in Blood Pressure (Systolic and Diastolic) at Week 52.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.74","spread":"1.2"},{"groupId":"OG001","value":"0.16","spread":"1.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.66","spread":"0.78"},{"groupId":"OG001","value":"0.11","spread":"0.79"}]}]}]},{"type":"SECONDARY","title":"Adverse Events From Run-in (Week -12) to Week 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"716","spread":null},{"groupId":"OG001","value":"845","spread":null},{"groupId":"OG002","value":"2389","spread":null},{"groupId":"OG003","value":"383","spread":null},{"groupId":"OG004","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-26","description":"Number of hypoglycaemic episodes from Week 0 to Week 26, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Hypoglycaemic Episodes Weeks 0-52","description":"Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"53","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"57","spread":null},{"groupId":"OG002","value":"42","spread":null},{"groupId":"OG004","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":159},"commonTop":["Nausea","Diarrhoea","Nasopharyngitis","Headache","Lipase Increased"]}}}